SPORE in Ovarian Cancer

卵巢癌中的孢子

• 批准号: 10222600
• 负责人: IE-MING SHIH
• 金额: $ 230.48万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-18 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10222600
• 关键词: Address; Adjuvant Therapy; Affect; Biostatistics Core; Blood; Cancer Biology; Cancer Etiology; Cancer Patient; Carboplatin; Carcinoma; Carcinoma in Situ; Cervical; Cessation of life; Clinical; Clinical Data; Combined Modality Therapy; Complex; DNA Damage; Data; Detection; Developed Countries; Development; Diagnosis; Disease; Disease remission; Drug resistance; Early Diagnosis; Early treatment; Ensure; Five-Year Plans; Funding; Future; Genetic; Genomics; Goals; Histologic; Incidence; Institution; Laboratory Research; Lesion; Libraries; Liquid substance; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of ovary; Measurable; Medical; Molecular; Molecular Genetics; Monitor; Morbidity - disease rate; New Agents; Operative Surgical Procedures; Outcome; Ovarian; Ovarian Carcinoma; Paclitaxel; Pathologic; Pathology; Pathway interactions; Patient advocacy; Patients; Pennsylvania; Perioperative; Platinum; Prevention; Progress Review Group; Progression-Free Survivals; Proteomics; Recurrent disease; Reproduction spores; Research; Research Project Grants; Resistance; Resources; Risk Marker; SYK gene; Scientist; Screening for Ovarian Cancer; Serous; Specimen; Technology; Testing; TimeLine; Translating; Translational Research; Translations; Treatment outcome; Tube; Tumor Biology; Tyrosine Kinase Inhibitor; United States; Universities; Uterine cavity; Woman; Work; anticancer research; antitumor effect; base; biobank; biomarker identification; cancer cell; cancer therapy; career; chemotherapy; clinical application; collaborative environment; combat; cytotoxic; drug development; effective therapy; human capital; improved; inhibitor/antagonist; innovation; mortality; multimodality; neoplastic cell; novel; novel strategies; novel therapeutic intervention; pre-clinical; programs; success; technology development; tumor; tumor DNA; tumor heterogeneity

OVARIAN CANCER SPORE: SUMMARY Ovarian cancer is one of the most aggressive cancers in women in the United States and a major cause of cancer morbidity and mortality. This Johns Hopkins-University of Pennsylvania Ovarian Cancer SPORE application focuses on reducing ovarian cancer incidence and mortality by translating new laboratory research discoveries made in our institution into improvements in ovarian cancer detection and treatment. This highly translational program contains four hypothesis-driven Research Projects, three Core Resources, the Career Enhancement Program, and the Developmental Research Program. The objective of Project 1 is to determine whether detection of tumor cells from liquid-based cervical fluid specimens, endometrial cavity brushing and/or circulating tumor DNA (ctDNA) from blood can identify early and low-volume ovarian high-grade serous carcinoma (HGSC), the most common type of ovarian carcinoma, or its precursor lesion, serous tubal intraepithelial carcinoma. The goal of Project 2 and Project 3 is to provide critical preclinical and early clinical data for developing more effective combined therapy to treat advanced ovarian HGSC, especially for recurrent diseases. Specifically, Project 2 is to optimize synthetic lethality in high-grade ovarian serous ovarian cancer by using ATR inhibitor and PARP inhibitor. Project 3 based on a recent discovery made by our team proposes to apply BET inhibitors for overcoming platinum resistance. Project 4 aims to determine that inhibition of Spleen Tyrosine Kinase (SYK) activity sensitizes ovarian cancer cells to the cytotoxic effect of paclitaxel, and determine if SYK inhibitor represents a promising new agent to be combined with (weekly) paclitaxel for the treatment of advanced ovarian cancer. These Projects are supported by an Administrative Core, a Biorepository/Pathology Core, and a Biostatistics Core. Finally, the Career Enhancement and Developmental Research Programs comprise pipelines of human capital and innovative ideas, respectively, which will fuel future SPORE advances. This application is strongly supported by institutional commitment to ensure its success.

卵巢癌孢子：总结